Romito O, Lemettre A, Chantome A, Champion O, Couty N, Ouldamer L
Mol Oncol. 2024; 18(8):1853-1865.
PMID: 38480668
PMC: 11306528.
DOI: 10.1002/1878-0261.13631.
Grunt T, Wagner R, Ries A, Berghoff A, Preusser M, Grusch M
Int J Oncol. 2024; 64(3).
PMID: 38214315
PMC: 10807641.
DOI: 10.3892/ijo.2024.5612.
Fei W, Yan J, Wu X, Yang S, Zhang X, Wang R
Theranostics. 2023; 13(8):2471-2491.
PMID: 37215569
PMC: 10196822.
DOI: 10.7150/thno.82189.
Lemberger L, Wagner R, Heller G, Pils D, Grunt T
Cancers (Basel). 2022; 14(23).
PMID: 36497485
PMC: 9737127.
DOI: 10.3390/cancers14236004.
Mir S, Wong S, Narasimhan K, Esther C, Ji S, Burla B
Metabolites. 2021; 11(9).
PMID: 34564414
PMC: 8469522.
DOI: 10.3390/metabo11090597.
Lysophosphatidic Acid Signaling in Cancer Cells: What Makes LPA So Special?.
Balijepalli P, Sitton C, Meier K
Cells. 2021; 10(8).
PMID: 34440828
PMC: 8394178.
DOI: 10.3390/cells10082059.
Effects and mechanisms of Eps8 on the biological behaviour of malignant tumours (Review).
Luo K, Zhang L, Liao Y, Zhou H, Yang H, Luo M
Oncol Rep. 2021; 45(3):824-834.
PMID: 33432368
PMC: 7859916.
DOI: 10.3892/or.2021.7927.
Lysophosphatidic Acid Upregulates Recepteur D'origine Nantais Expression and Cell Invasion via Egr-1, AP-1, and NF-κB Signaling in Bladder Carcinoma Cells.
Khoi P, Li S, Thuan U, Sah D, Kang T, Nguyen T
Int J Mol Sci. 2020; 21(1).
PMID: 31906413
PMC: 6981588.
DOI: 10.3390/ijms21010304.
The Mechanisms Underlying PTEN Loss in Human Tumors Suggest Potential Therapeutic Opportunities.
Chang H, Cai Z, Roberts T
Biomolecules. 2019; 9(11).
PMID: 31703360
PMC: 6921025.
DOI: 10.3390/biom9110713.
Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside.
Xu Y
Cancers (Basel). 2019; 11(10).
PMID: 31658655
PMC: 6826372.
DOI: 10.3390/cancers11101523.
Inhibitory short peptides targeting EPS8/ABI1/SOS1 tri-complex suppress invasion and metastasis of ovarian cancer cells.
Yu X, Liang C, Zhang Y, Zhang W, Chen H
BMC Cancer. 2019; 19(1):878.
PMID: 31488087
PMC: 6727365.
DOI: 10.1186/s12885-019-6087-1.
Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells.
Chen R, Yung M, Xuan Y, Zhan S, Leung L, Liang R
Commun Biol. 2019; 2:281.
PMID: 31372520
PMC: 6668395.
DOI: 10.1038/s42003-019-0508-1.
Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts.
Radhakrishnan R, Ha J, Jayaraman M, Liu J, Moxley K, Isidoro C
Cancer Lett. 2018; 442:464-474.
PMID: 30503552
PMC: 7780843.
DOI: 10.1016/j.canlet.2018.11.023.
Lysophospholipid Signaling in the Epithelial Ovarian Cancer Tumor Microenvironment.
Xu Y
Cancers (Basel). 2018; 10(7).
PMID: 29987226
PMC: 6071084.
DOI: 10.3390/cancers10070227.
LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response.
Ha J, Radhakrishnan R, Jayaraman M, Yan M, Ward J, Fung K
Cancer Res. 2018; 78(8):1923-1934.
PMID: 29386184
PMC: 5899640.
DOI: 10.1158/0008-5472.CAN-17-1624.
Selective export of autotaxin from the endoplasmic reticulum.
Lyu L, Wang B, Xiong C, Zhang X, Zhang X, Zhang J
J Biol Chem. 2017; 292(17):7011-7022.
PMID: 28298439
PMC: 5409469.
DOI: 10.1074/jbc.M116.774356.
Expressions of lysophosphatidic acid receptors in the development of human ovarian carcinoma.
Si J, Su Y, Wang Y, Yan Y, Tang Y
Int J Clin Exp Med. 2016; 8(10):17880-90.
PMID: 26770382
PMC: 4694282.
Expression and function of lysophosphatidic acid receptors (LPARs) 1 and 3 in human hepatic cancer progenitor cells.
Zuckerman V, Sokolov E, Swet J, Ahrens W, Showlater V, Iannitti D
Oncotarget. 2015; 7(3):2951-67.
PMID: 26701886
PMC: 4823083.
DOI: 10.18632/oncotarget.6696.
Ceramide limits phosphatidylinositol-3-kinase C2β-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid.
Kitatani K, Usui T, Sriraman S, Toyoshima M, Ishibashi M, Shigeta S
Oncogene. 2015; 35(21):2801-12.
PMID: 26364609
PMC: 4791218.
DOI: 10.1038/onc.2015.330.
A metabolomic approach to identifying platinum resistance in ovarian cancer.
Poisson L, Munkarah A, Madi H, Datta I, Hensley-Alford S, Tebbe C
J Ovarian Res. 2015; 8:13.
PMID: 25880539
PMC: 4396147.
DOI: 10.1186/s13048-015-0140-8.